Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Pathol Res Pract. 2022 Sep;237:154024. doi: 10.1016/j.prp.2022.154024. Epub 2022 Jul 13.
Colorectal cancer (CRC) is known for its high mortality rate and affects more men than women. The treatment requires invasive surgical interventions, however, the progression of CRC metastasis is difficult to control in most cases. Mesenchymal stem cells (MSCs) with their outstanding characteristics have been widely used in the treatment of degenerative diseases as well as cancers. They affect the tumor microenvironment through either cell-cell interactions or communications with their secretome. While stem cells may represent a dual role in tumor proliferation and progression, exosomes have attracted much attention as a cell-free therapy in CRC treatment. Exosomes derived from native or genetically modified MSCs, as well as exosomal microRNAs (miRNAs), have been evaluated on CRC progression. Moreover, MSC-derived exosomes have been used as a carrier to deliver anticancer agents in colorectal cancer. In this review, we overview and discuss the current knowledge in both stem cell-based and cell-free exosome therapy of CRC.
结直肠癌(CRC)以其高死亡率为特征,且男性发病率高于女性。治疗需要侵入性的手术干预,然而,CRC 转移的进展在大多数情况下难以控制。间充质干细胞(MSCs)具有出色的特性,已被广泛用于治疗退行性疾病和癌症。它们通过细胞-细胞相互作用或与细胞外泌体的通讯来影响肿瘤微环境。虽然干细胞在肿瘤增殖和进展中可能具有双重作用,但外泌体作为 CRC 治疗的无细胞疗法引起了广泛关注。源自天然或基因修饰的 MSCs 的外泌体以及外泌体 microRNAs(miRNAs)已在 CRC 进展中进行了评估。此外,MSC 衍生的外泌体已被用作载体来递送至结肠癌中的抗癌药物。在这篇综述中,我们综述和讨论了基于干细胞和无细胞外泌体治疗 CRC 的最新知识。
Clin Transl Oncol. 2022-6
Adv Biol (Weinh). 2022-2
Med Oncol. 2024-7-20
Stem Cell Res Ther. 2022-4-1
Curr Stem Cell Res Ther. 2024